title: Exploring novel therapeutic options in T-LGL, including epigenetic modulation: a case report.
authors.forename: Regina
authors.initials: R
authors.lastname: Miftakhova
authors.forename: Tove
authors.initials: T
authors.lastname: Sandberg
authors.forename: Sharon
authors.initials: S
authors.lastname: Longno
authors.forename: Peter
authors.initials: P
authors.lastname: Bjork
authors.forename: Sven
authors.initials: S
authors.lastname: Bjornsson
authors.forename: Vladimir L J
authors.initials: VL
authors.lastname: Lazarevic
authors.forename: Jenny
authors.initials: J
authors.lastname: Persson
authors.forename: Anders
authors.initials: A
authors.lastname: Bredberg
mesh_terms: D015703:Antigens, CD / Q000032:analysis; D002455:Cell Division; D003165:Complement System Proteins / Q000502:physiology; D018899:CpG Islands; D019175:DNA Methylation; D047628:Estrogen Receptor alpha / Q000235:genetics; D019942:Genes, p16; D015789:HLA-A2 Antigen / Q000032:analysis; D006801:Humans; D054066:Leukemia, Large Granular Lymphocytic / Q000175:diagnosis / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000494:pharmacology; D011401:Promoter Regions, Genetic; D018168:Receptors, Retinoic Acid / Q000235:genetics; D000072482:Retinoic Acid Receptor alpha; D013601:T-Lymphocytes / Q000737:chemistry / Q000187:drug effects / Q000473:pathology; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D015703:Antigens, CD; C506487:ESR1 protein, human; D047628:Estrogen Receptor alpha; D015789:HLA-A2 Antigen; D016853:Muromonab-CD3; C000607071:RARA protein, human; D018168:Receptors, Retinoic Acid; D000072482:Retinoic Acid Receptor alpha; D003165:Complement System Proteins